Skip to main content
PLOS One logoLink to PLOS One
. 2025 Oct 22;20(10):e0318140. doi: 10.1371/journal.pone.0318140

Targeted pathogen profiling of ancient feces reveals common enteric infections in the Rio Zape Valley, 725–920 CE

Drew Capone 1,*,#, David Holcomb 2,#, Amanda Lai 3, Tim Meade 4, Karl Reinhard 4,5, Joe Brown 2
Editor: Elham Kazemirad6
PMCID: PMC12543138  PMID: 41124126

Abstract

DNA analysis of ancient, desiccated feces – termed paleofeces – can unlock insights into the lives of ancient peoples, including through examination of the gut microbiome and identification of specific pathogens and parasites. We collected desiccated feces from the Cave of the Dead Children (La Cueva de Los Muertos Chiquitos) in the Rio Zape Valley in Mexico dated to 725–920 CE, for targeted pathogen analysis. First, we extracted DNA with methods previously optimized for paleofeces. Then, we applied highly sensitive modern molecular tools (i.e., PCR pre-amplification followed by multi-parallel qPCR) to assess the presence of 30 enteric pathogens and gut microbes. We detected ≥1 pathogen or gut microbe associated gene in each of the ten samples and a mean of 3.9 targets per sample. The targets detected included Blastocystis spp. (n = 7), atypical enteropathogenic E. coli (n = 7), Enterobius vermicularis (n = 6), Entamoeba spp. (n = 5), enterotoxigenic E. coli (n = 5), Shigella spp./enteroinvasive E. coli (n = 3), Giardia spp. (n = 2), and E. coli O157:H7 (n = 1). The protozoan pathogens we detected (i.e., Giardia spp. and Entamoeba spp.) have been previously detected in paleofeces via enzyme-linked immunoassay (ELISA), but not via PCR. This work represents the first detection of Blastocystis spp. atypical enteropathogenic E. coli, enterotoxigenic E. coli, Shigella spp./enteroinvasive E. coli, and E. coli O157:H7 in paleofeces. These results suggest that enteric infection may have been common among the Loma San Gabriel people, who lived in the Rio Zape Valley in Mexico during this period.

Introduction

Ancient peoples left behind a wealth of evidence, but direct biological evidence is scarce and often highly decayed. Sensitive modern molecular methods offer the opportunity to advance our knowledge of these ancient civilizations. One piece of the puzzle is desiccated human fecal material, which has been recovered at cave sites across the world [15]. Much can be learned from these materials; ancient stool samples, termed paleofeces, can offer insights into dietary practices, human migration, and pathogen exposures.

The ova of soil transmitted helminths (i.e., intestinal worms) have been a focus of ancient feces research for decades because they are highly persistent in the environment and are large enough to view via microscopy [610]. However, it is accepted in modern clinical practice that microscopy for helminth ova requires highly trained microscopists and there is potential for misclassification. The visual identification of ova in ancient feces – including Ascaris and hookworm – has therefore generated much debate regarding the veracity of the claims [1117].

Modern molecular methods – including metagenomics and polymerase chain reaction (PCR) – are highly sensitive and specific [18,19]. However, nucleic acid fragments, including microbial DNA in ancient feces are highly degraded and usually present at low concentrations [20]. Given the poor analytical sensitivity associated with metagenomic methods for targets present at low concentrations, analysis is limited to communities and generally not specific pathogens without deep sequencing [21,22]. PCR is highly sensitive and specific, but specialized methods are required to maximize recovery and prevent contamination in laboratory handling [20]. Refinement of existing methods, combined with state-of-the-science molecular approaches, is increasingly being used for sensitive detection of fecal microbes in ancient feces [23,24]. Such knowledge could expand our understanding of the burden of disease among ancient peoples and pathogen transmission among different groups. Our research objective was to: (1) apply modern stool based molecular diagnostics to ancient fecal samples; and (2) assess the enteric pathogen profile of these samples.

Methods

Study site and population

The Cave of the Dead Children (La Cueva de los Muertos Chiquitos) in Rio Zape Valley of Mexico was excavated in 1957 and 1960 in 5X5 foot grids and 6-inch levels [25]. It exists in a low-humidity area, which slowed the degradation of the cave’s contents via desiccation. Paleofeces was recovered from a midden in the back of the cave, which was composed of paleofeces, quids (i.e., masses of leaf base fiber typically expelled after chewing), cordage, diverse botanical remains and bones (Brooks et al. 1962: Table 1) [25]. This midden ranged from surface to 30 inches deep. It was covered by a paved activity surface, which appeared to be from the final use of the cave.

Table 1. Dietary observations by provenience (Grid/Depth) and Meade’s 1994 laboratory analysis numbers [26].

Grid/Depth Meade Lab # Macro Pollen
B3 0–4“ 3 Agave, grass florette, Sunflower type, Malvaceae,
B3 8–12“ 8 Ground maize, Chenopodium seeds, sunflower achenes Apiaceae, sunflower type
B3 8–12“ 8 Juniper berries, ground maize Maize, sunflower type, Solanaceae
B3 24–30“ 13 Agave fiber, ground maize, Chenopodium seeds, Sporobolus caryopses, maize
B3 24–30“ 13 Opuntia pads, Physalis fruit, rodent bones No economic pollen
B3 16–20“ 17 Agave fiber Brassicaceae, sunflower type
B4 16–20“ 1a Agave fiber, sunflower achenes Cactaceae, Caryophyllaceae, Solanaceae, sunflower type
B4 16–20“ 1b Maize kernels Maize
B4 16–20“ 26 Agave, ground maize No economic pollen
B4 20–24“ 20 Opuntia pads, Agave fiber, maize, beans, rodent bones No economic pollen

Meade previously analyzed 49 paleofeces from the cave for diverse proveniences for all types of dietary remains including pollen, seeds, fibers, and phytoliths [26]. Samples were classified as human or non-human origin based on observations of these materials, as summarized by Reinhard 2017 [27]. The approach included four stages of observation, including during excavation, preliminary lab examination, rehydration and analysis of coprolite components. In 2020, we developed CoproID molecular analysis, which can be added as an additional method of inferring human origin and was applied to the Zape Cave samples [28]. All the paleofeces analyzed by Meade were consistent with human fecal material, and we randomly selected 10 samples from this collection for our analysis. In addition, the previous dietary analysis of the ten samples included in this analysis show distinct dietary data, which confirms that the samples are derived from distinct defecation events throughout the time the midden was used (Table 1) [26].

Unprocessed paleofeces from Meade’s 1993 [26] study were curated for future analysis in the Pathoecology Laboratory of the School of Natural Resources, University of Nebraska-Lincoln, until 2024. Currently, they are part of the permanent Paleoparasitology Collection in the Harold W. Manter Laboratory of Parasitology, University of Nebraska State Museum.

Biogenic crystals were abundant in the 49 paleofeces analyzed by Meade [26]. Hundreds of phytoliths per gram of sample were recovered from agave, cactus, and squash. Agave phytoliths were recovered from 25 of the coprolites. Cactus and prickly pear phytoliths were present in 12 samples, and squash phytoliths were present in 5 samples. In prevalence and abundance, Agave phytoliths were overwhelmingly recovered from the coprolites. Agave was the most common food eaten at the site, and many phytoliths were liberated from the leaf bases during chewing. Agave epidermis was also found. Entire, swallowed quids were evident in some of the coprolites. Thus, the macroscopic evidence from this previous study supports the phytolith evidence that Agave was the major food at the site and that it is the main source of dietary abrasives. The macroscopic and pollen evidence of foods from the coprolites include fruits from ground cherry, maize, sunflower, pigweed and goosefoot.

Evidence of human association also came from 49 dental casts made from quids [29]. The casts from the same midden deposits as the coprolites showed a complete spectrum of age groups ranging from children to young adults and to old adults. They also show that the Zape Cave diet was abrasive. Analysis of the quids and coprolites shows that the most consistent source of dietary abrasives was from the prehistoric dietary use of Agave.

Three palaeofeces samples from the same provenience represented by the Meade paleofeces series were submitted to DirectAMS for accelerator mass spectrometry radiocarbon dating measurements [30]. The three paleofeces samples were dated to 665–770, 770–953, and 778–986 CE.

While palaeofaeces are not subject to the Native American Graves Protection and Repatriation Act (NAGPRA) or other regulations, indigenous populations with strong cultural ties to the specimens were consulted as part of previous work with these samples [30]. No permits were required for the described study, which complied with all relevant regulations.

Nucleic acid extraction

Several precautions were taken to prevent contamination of the samples. Extractions were performed in Class IIA biological safety cabinet (BSC) that was disinfected with 10% bleach, 70% ethanol, and UV before and after use. This BSC was in a separate room from where PCR was performed. All materials were either single use items that had been purchased sterile and only opened inside the biological safety cabinet, or had been autoclaved, washed, autoclaved again, and flame sterilized before use. In addition, we purchased new bottles of reagents for this work.

We adapted nucleic acid extraction “Method B” as described in Hagan et al. 2020 [20], which optimized extraction methods for the recovery of DNA from paleofeces. The samples were high in fiber [29] which made them rigid and required an initial grinding step that was not previously described. After carefully breaking off small quantities of paleofeces inside a sterile whirl-pak bag (Nasco, Madison, Wisconsin), we transferred approximately 25–50 mg of paleofeces to a sterile 50mL tissue grinding tube (VWR, Radnor, Pennsylvania). The fecal material was ground into a powder by rotating the handle of the tissue grinding tube and then contents were carefully poured into a 2 mL PowerBead tube (Qiagen, Hilden, Germany) containing garnet beads. Additional material was ground and transferred until 200 mg of fecal material was achieved. We extracted 1–3 replicates of each sample depending on the quantity of fecal material available.

After loading bead tubes with paleofeces, we followed the methods described in Hagan et al. 2020 [20]. First, we added 400 µL of 0.5 M EDTA (VWR, Radnor, Pennsylvania), 100 µL of Proteinase K (ThermoFisher, Waltham, Massachusetts), and 750 µL of PowerBead Solution (Qiagen, Hilden, Germany) to each sample in the PowerBead tube. Then, the bead beating tube was placed inside a 50mL tube and gently rotated on a tube roller four hours at room temperature. Next, we vortexed samples for 10 minutes using a Vortex-Genie mixer (Scientific Industries, Bohemia, New York) at maximum speed and then centrifuged samples at 11,000 x g for five minutes.

Next, we carefully but firmly pushed the bottom of a Zymo-Spin V reservoir (Zymo, Irvine, California) into a MinElute column (Qiagen, Hilden, Germany) and placed the device into a sterile 50 mL centrifuge tube. We added 14 mL of Qiagen PB buffer and the entire supernatant from the bead beating tube into the chamber of the Zymo-Spin V reservoir. Then the tube was centrifuged for 4 minutes at 2000 x g, rotated 90°, and centrifuged at 2000 x g for an additional 2 minutes. Afterwards, we removed the MinElute column from the reservoir, inserted the column into a 2mL micro collection tube and centrifuged at 11,000 x g for two minutes to dry the column. Next, we pipetted 700 µL of Qiagen PE buffer (Qiagen, Hilden, Germany) into the MinElute column, centrifuged for 2 minutes at 11,000 x g, discarded the flow-through and then repeated this step with fresh PE buffer. Finally, we added 30 µL of Qiagen EB buffer (Qiagen, Hilden, Germany) to the MinElute column, incubated at room temperature for 5 minutes, centrifuged at 11,000 x g, retained the flow-through, and repeated this step. This process resulted in 60 µL of template, which was stored at 4°C for less than 24 hours and then stored at −80°C. The average concentration of dsDNA in our extracts – measured via a Qubit dsDNA Assay Kit on a Qubit 4 Fluorometer (ThermoFisher, Waltham, Massachusetts) – was 5.1 nanograms per microliter (range: 0.30–19.6).

On each day of extractions, we included one negative extraction control to monitor for contamination. We did not spike in extraction control material to the samples to limit the potential for contamination.

Pre-amplification

We used the TaqMan PreAmp Master Mix Kit to pre-amplify our target sequences and lower our limit of detection (ThermoFisher, Waltham, Massachusetts). First, we pooled the 38 forward and 38 reverse primers (IDT, Coralville, Iowa) such that concentration of each primer was 0.18 µM, which equates to the final concentration required by the kit. Then we prepared 20 µL pre-amplification PCR reactions for each sample according to the manufacturer instructions, which included TaqMan PreAmp Mastermix (10 µL), the diluted primer pool (5 µL), DNA template (5 µL). The resulting reaction was run on a Bio-Rad CFX 96 Touch thermocycler (Bio-Rad, Hercules, CA) with an initial activation at 95°C for 10 minutes, followed by 14 cycles of 95°C for 15 seconds followed by 60°C for 4 minutes.

Real-time PCR

We developed a custom TaqMan Array Card (TAC) according to Liu et al. 2013 [31] and 2016 [32] (Table S1, Table S2). The pathogens and gut microbes we assessed included helminths (Ancylostoma duodenale, Ascaris lumbricoides, Enterobius vermicularis, Hymenolepis nana, Necator americanus, Strongyloides stercolaris, and Trichuris trichiura), protozoa (Acanthamoeba spp., Balantidium coli, Blastocystis spp., Cystoisospora belli, Cyclospora cayetanensi, Cryptosporidium spp., Enterocytozoon bieneusi, Encephalitozoon intestinalis, Entamoeba hystolytica, Entamoeba spp., Giardia spp.), and bacteria (Campylobacter jejuni/coli, Clostridium difficile, E. coli O157:H7, enteroaggregative E. coli, enteropathogenic E. coli, enterotoxigenic E. coli, Helicobacter pylori, Shigella/enteroinvasive E. coli, Plesiomonas shigelloides, Salmonella spp., shiga-toxin producing E. coli, Yersinia enterocolitica). The assays used were previously validated on modern fecal material with 100% sensitivity and 95%−100% specificity [32]. The average amplicon length for an assay was 116 bp (minimum = 54 bp, maximum = 238 bp) (S2 Table). In addition, the card included assays for enteric 16S rRNA and phocine herpes virus (PhHPV) [32]. The enteric 16S rRNA assay –described in Rousselon et al. 2004 [33] – was designed to detect a cluster of phylotypes, called Fec1, corresponding to 5% of the human fecal microflora [32].

The TAC was prepared by combining 6.67 µL of pre-amplification product [34], with 31.3 µL of molecular grade water, 2 µL of a synthetic DNA sequence matching the PhHPV assay to monitor inhibition (106 copies per µL), and 60 µL of AgPath-ID™ One-Step RT-PCR Reagents (Applied Biosystems, Waltham, MA). We used the standard TAC cycling conditions with a 1°C/s ramp rate between all steps: 45°C for 20 minutes, 95°C for 10 minutes, then 45 cycles of 95°C for 15 seconds and 60°C for 1 minute [31,32]. The TAC performance was evaluated using an 8-fold dilution series (109-102 gene copies per reaction) of an engineered combined positive control that was developed using methods from Kodani and Winchell 2012 [35]. The linearity and efficiency the targets were within normative standards (linearity: 0.97-1.0, efficiency: 87%−102%) (S2 Table). Each day of TAC analysis, one PCR positive control and one negative extraction control were analyzed. Quantification cycle (Cq) values were determined by manual thresholding and included comparison of each assay’s fluorescent signal against the daily negative and positive controls (S1 Fig). Any target that amplified past a Cq of 40 was categorized as negative to reduce the potential for false positives [32]. The theoretical limit of detection – a result of the dilutions used – was 60 gene copies per gram solids (S3 Table).

Digital PCR

We performed digital PCR with a QIAcuity 4 instrument (Qiagen, Hilden, Germany) to assess the presence of human mitochondrial (mtDNA) DNA in the paleofeces samples to assess if fecal material was of human origin (S4 Table) [36]. Human mtDNA is present in human feces because intestinal epithelial cells and leucocytes are shed from the intestinal lining into fecal matter. This assay has demonstrated high sensitivity (100%) and specificity (97%) to fresh human feces. We prepared reactions with QIAcuity Probe Mastermix, 200 nM forward and reverse primers, 800 nM probe, and 2 µL of raw template (i.e., no pre-amplification was performed). Thermocycling conditions were 95°C for two minutes, followed by 45 cycles of 95°C for 15 seconds and 55°C for 60 seconds. We included one positive and one negative control on each dPCR nanoplate. We differentiated positive and negative partitions by manual thresholding between the bands of the positive and negative controls. Samples with less than three positive partitions were classified as negative to reduce the potential for false positives.

Results

Controls

Assays for the four PCR positive controls exhibited positive amplification as expected (Cq ~ 18). There was no positive amplification for any target in the four negative extraction controls, except for the 16S rRNA assay. Microbial DNA contamination of Taq polymerase in PCR mastermix has been documented [37,38] including for the 16S rRNA gene [39,40]. According to the quality control of the manufacturer, the 20 µL pre-amplification reactions contained ≤2 copies of the 16S rRNA gene [40]. The pooled primers in the reaction included primers for the 16S assay, which if present, may have amplified this contamination. The spiked inhibition control – which was a synthetic DNA sequence – amplified consistently (Cq ~ 20) for all samples.

Molecular Results

We detected ≥1 enteric pathogen or gut microbe in each of the ten paleofeces from Mexico and a mean of 3.9 targets per sample out of the 30 assessed (Table 2, S5 Table). The targets detected in the ten samples included Blastocystis spp. (n = 7), atypical enteropathogenic E. coli (n = 7), Enterobius vermicularis (n = 6), Entamoeba spp. (n = 5), enterotoxigenic E. coli (n = 5), Shigella spp./enteroinvasive E. coli (n = 3), Giardia spp. (n = 2), and E. coli O157:H7 (n = 1). One sample was positive for human mtDNA via dPCR at a high concentration (approximately 105 gene copies/gram paleofeces) and was only positive for Blastocystis spp. While, human mtDNA was not detected in the remaining nine samples, all 10 samples were positive for the enteric 16S rRNA target.

Table 2. Prevalence of molecular targets.

Target Prevalence N (out of 10)
enteric 16S rRNA 100% 10
Blastocystis spp 70% 7
Enteropathogenic E. coli (atypical) 70% 7
Enterobius vermicularis (pinworm) 60% 6
Entamoeba spp. 50% 5
Enterotoxigenic E. coli 50% 5
Enteropathogenic E. coli (typical) 30% 3
Shigella/EIEC 30% 3
Giardia spp. 20% 2
E. coli O157:H7 10% 1
human mtDNA 10% 1*

Note: The following were not detected: Acanthamoeba spp., Ancylostoma duodenale.

Ascaris lumbricoides, Blantidium coli, Cystoisospora belli, Cyclospora cayetanensi, Campylobacter jejuni & coli, Clostridioides difficile B, Cryptosporidium spp., Enterocytozoon bieneusi, Encephalitozoon intestinalis, Entamoeba histolytica, Hymenolepis nana, Helicobacter pylori, Necator americanus, Plesiomonas shigelloides, Salmonella spp., Strongyloides stercolaris, Trichuris trichiura, Yersinia enterocolitica, Enteroaggregative E. coli, Shiga-toxin producing E. coli. EIEC = Enteroinvasive E. coli.

*The positive sample exhibited a strong positive signal.

This assay was designed for human feces, but may cross react with some animal feces [33].

We analyzed replicates from nine of the ten samples. This included six samples in duplicate and three samples in triplicate, which was limited by the mass of material available. Among these nine samples, there were 40 instances where a pathogen associated gene was detected in a sample and could be compared against detection in the other replicate samples. We observed perfect concordance (i.e., both duplicates or all three triplicates positive) among 60% (n = 24/40) of replicates, moderate concordance (two out of three triplicates positive) among 5.0% (n = 2/40), and poor concordance (one detection out of two or three replicates) among 35% (n = 14/40).

Discussion

We detected diverse enteric pathogens in 1,100−1,300 year-old paleofeces from Mexico. The 60% prevalence of pinworm (i.e., Enterobius vermicularis) we observed is greater than the 34% (n = 34/100) prevalence determined via microscopy on paleofeces from the same cave in Mexico. PCR has greater sensitivity than microscopy, but our small sample size suggests cautious interpretation. Protozoan pathogens we detected, including Giardia spp. [5] and Entamoeba spp. [41] have been previously detected in paleofeces via enzyme-linked immunoassay (ELISA), but have not via PCR. In addition, this work represents the first detection of Blastocystis spp., atypical enteropathogenic E. coli, enterotoxigenic E. coli, Shigella spp./enteroinvasive E. coli, and E. coli O157:H7 in paleofeces.

There is debate whether helminths other than pinworm were circulating among people in the Americas before the Columbian exchange began in 1492 [11]. The molecular detection of pinworm supports the use of qPCR assays, combined with microscopy and sequencing, to better understand which helminths were circulating in the Americas prior to the Columbian Exchange [23,24]. Given the potential for ova degradation, reported visual observations of hookworm and Ascaris ova in paleofeces from the Americas pre-1492 would be strengthened by further molecular validation. However, definitive conclusions should not be drawn from a small sample size of paleofeces from a single cave.

Several of the non-detect results contrast with previous findings. However, a non-detect does not indicate that the target was not initially present in the sample. It does indicate that we were unable to detect it with the methods used. For example, 61% (55/90) of paleofeces from the same cave in Mexico exhibited a strong positive signal for Cryptosporidium parvum via ELISA [42]. There are several possible explanations for this discrepancy. It is possible that the Cryptosporidium antigens measured had greater environmental persistence than the nucleic acids inside the oocysts. Second, our analysis was limited to ten samples. Analysis of other paleofeces samples from this cave may have detected Cryptosporidium. This discrepancy further highlights the importance of using multiple complementary assays when interpreting evidence from ancient fecal material.

Cautious interpretation is also warranted for the infrequent detection of human mtDNA. These paleofeces were previously identified as human based on dietary materials, morphology and size [1,42], but such analysis may be subjective. The presence of Enterobius vermicularis in most samples also provides strong evidence of human origin. Enterobius vermicularis is a human specific pathogen, though it can infect some species of apes [4345]. The detection of human mtDNA at a high concentration from one sample – and the detection of the enteric 16S rRNA assay in all samples – provides additional confidence that at least some of these paleofeces are from humans. Although, we did not test for mtDNA from animals.

Human mtDNA is often found at lower concentrations in human feces than genes from other microbial organisms [36,46] and its persistence in the environment, relative to the pathogenic genes we detected, is unclear. In our previous work with modern fecal material from school-age children, we found the concentration of enteric 16S rRNA was approximately 9,300 times greater than human mtDNA [47]. If these signals persisted at the same or similar rates, then this initial difference in concentration may explain why enteric 16S rRNA was observed above our limit of detection in each sample but human mtDNA was only detected in one sample.

If some or all these feces are from humans, then this study suggests poor sanitation among the Loma San Gabriel culture from 600-800 CE resulted in exposures to fecal wastes in the environment. Human and animal feces may contain enteric pathogens, which are transmitted via drinking water, soils, food, flies, and fomites [48,49]. Some of the pathogens we detected are zoonotic, meaning that they can be shed by animals as well as humans. For example, Shigella spp. is considered specific to humans, though the sample positive for Shigella spp. was negative for human mtDNA [50].

We used PCR to detect the presence or absence of genes that are found in specific microorganisms [19]. PCR requires prior knowledge of the target sequence, which limited our analysis to specific pathogen and gut microbe associated genes. Our pre-amplification and PCR methods were also limited to the specific target of interest and we were unable to provide information about other DNA sequences that may have been present. Metagenomics is an alternative method that involves sequencing all the genetic material in sample [18]. It provides the genetic code of the entire microbial community, including reads for known and unknown organisms. Metagenomic methods have been used to characterize microbial communities and reconstruct ancient microbial genomes from paleofeces [30,51,52]. Sequencing methods, however, have limitations in identifying microbial DNA at the genus or species level as we have done here. Metagenomics has a substantially higher limit of detection than PCR, and sequencing may miss low abundance genomes [21,22]. If genomes are similar, then bioinformatics pipelines may be unable to resolve species or genus-level details. Accurate identification also relies on the quality of reference databases. If these databases include misidentified genomes, or if specific genomes are not well represented in the database, then it may be challenging to accurately identify the aligned reads.

There are several limitations associated with this work. First, we analyzed a small number of samples from a single cave. An analysis of additional samples may have detected other pathogen-associated genes or a different prevalence of the genes we detected. We observed perfect concordance between replicates for most targets that we detected. Intra-stool heterogeneity has been demonstrated for enteric pathogen in modern feces [53]. We did not homogenize entire ancient fecal samples, which is common when working with fresh feces, and may have contributed to the heterogeneity in detection. The persistence of the gene targets in paleofeces is not well characterized. Evidently some pathogen associated genes persisted in the samples for 1,100−1,300 years, but it is unclear if other genes may have decayed beyond our ability to detect them. Damage and chemical modifications in ancient DNA—such as cytosine deamination—can be assessed through sequencing and bioinformatic analysis to help distinguish endogenous ancient DNA from modern contamination [54]. Uracil-DNA Glycosylase (UDG) treatment has been developed to remove uracil residues and repair resulting abasic sites [55]. While we did not employ these methods, they are primarily used in metagenomic studies and are less applicable to qPCR-based detection. However, the presence of deaminated nucleotides in ancient feces may have impaired primer and probe binding or amplification efficiency, potentially leading to underestimation of the prevalence of our target genes.

PCR inhibitors may have unique impacts on different PCR assays, and assay specific inhibition may have occurred given the large targets assays we used [56]. While our extraction methods had been optimized for paleofeces, we prioritized recovery of small DNA fragments by, in part, omitting inhibitor removal steps that would typically be used in fresh stool extractions [20]. Further, we did not conduct molecular analyses in a clean room dedicated to ancient DNA analysis [57]. While we worked under sterilized BSL2 conditions with sterile single use reagents and observed no contamination in our negative controls, we cannot completely rule out the potential for cross contamination. We did not perform UV surface sterilization of the paleofeces, as enteric pathogens replicate exclusively in the gut and are not part of endogenous soil microbiota. Potential surrounding soil contamination during excavation was highly unlikely to introduce these organisms to paleofeces surfaces. Finally, there is always a possibility of nonspecific amplification in PCR reactions, and if nonspecific amplification occurred, we may have overestimated the prevalence of the targets in our samples. However, we did not observe nonspecific amplification in our negative controls in this study or a previous study that used the same assays on a larger number of samples [47].

We detected genes associated with eight enteric pathogens and one common intestinal microbe (i.e., Blastocystis), many of which have never been detected before in paleofeces. These results indicate that modern molecular techniques are an effective tool to screen paleofeces – and potentially other ancient samples – for multiple gene-based targets of interest. The application of these methods to other ancient samples offers the potential to expand our understanding of how ancient peoples lived and the pathogens that may have impacted their health.

Supporting information

S1 Table. qPCR assays.

(DOCX)

pone.0318140.s001.docx (80.8KB, docx)
S2 Table. qPCR QA/QC.

(DOCX)

pone.0318140.s002.docx (46.1KB, docx)
S1 Fig. Amplification curves.

(DOCX)

pone.0318140.s003.docx (166.8KB, docx)
S3 Table. MIQE Checklist.

(DOCX)

pone.0318140.s004.docx (50.4KB, docx)
S4 Table. dPCR assay.

(DOCX)

pone.0318140.s005.docx (56.5KB, docx)
S5 Table. Supplemental data file.

(XLSX)

pone.0318140.s006.xlsx (9.9KB, xlsx)

Data Availability

All relevant data are within the paper and its Supporting Information.

Funding Statement

D.C. was supported in part by a National Institute of Environmental Health Sciences T32 Fellowship (5T32ES007018). The authors declare no competing financial interest. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.

References

  • 1.Shillito L-M, Whelton HL, Blong JC, Jenkins DL, Connolly TJ, Bull ID. Pre-Clovis occupation of the Americas identified by human fecal biomarkers in coprolites from paisley caves, oregon. Sci Adv. 2020;6(29):eaba6404. doi: 10.1126/sciadv.aba6404 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Jiménez FA, Gardner SL, Araújo A, Fugassa M, Brooks RH, Racz E, et al. Zoonotic and human parasites of inhabitants of Cueva de los Muertos Chiquitos, Rio Zape Valley, Durango, Mexico. J Parasitol. 2012;98(2):304–9. doi: 10.1645/GE-2915.1 [DOI] [PubMed] [Google Scholar]
  • 3.Karpinski E, Mead JI, Poinar HN. Molecular identification of paleofeces from Bechan Cave, southeastern Utah, USA. Quaternary International. 2017;443:140–6. doi: 10.1016/j.quaint.2017.03.068 [DOI] [Google Scholar]
  • 4.Sobolik KD, Gremillion KJ, Whitten PL, Watson PJ. Technical note: Sex determination of prehistoric human paleofeces. Am J Phys Anthropol. 1996;101(2):283–90. doi: 10.1002/(sici)1096-8644(199610)101:2<283::aid-ajpa10>3.0.co;2-w [DOI] [PubMed] [Google Scholar]
  • 5.Faulkner CT. Prehistoric Diet and Parasitic Infection in Tennessee: Evidence from the Analysis of Desiccated Human Paleofeces. Am antiq. 1991;56(4):687–700. doi: 10.2307/281546 [DOI] [Google Scholar]
  • 6.Reinhard KJ. Archaeoparasitology in North America. Am J Phys Anthropol. 1990;82(2):145–63. doi: 10.1002/ajpa.1330820204 [DOI] [PubMed] [Google Scholar]
  • 7.Morrow JJ, Reinhard KJ. The Paleoepidemiology ofEnterobius vermicularis(Nemata: Oxyuridae) Among the Loma San Gabriel at La Cueva de los Muertos Chiquitos (600–800 CE), Rio Zape Valley, Durango, Mexico. Comparative Parasitology. 2018;85(1):27–33. doi: 10.1654/1525-2647-85.1.27 [DOI] [Google Scholar]
  • 8.Langgut D. Mid-7th century BC human parasite remains from Jerusalem. Int J Paleopathol. 2022;36:1–6. doi: 10.1016/j.ijpp.2021.10.005 [DOI] [PubMed] [Google Scholar]
  • 9.Rabinow S, Wang T, Wilson RJA, Mitchell PD. Using parasite analysis to identify ancient chamber pots: An example of the fifth century CE from Gerace, Sicily, Italy. J Archaeological Science: Reports. 2022;42:103349. doi: 10.1016/j.jasrep.2022.103349 [DOI] [Google Scholar]
  • 10.Cano RJ, Rivera-Perez J, Toranzos GA, Santiago-Rodriguez TM, Narganes-Storde YM, Chanlatte-Baik L, et al. Paleomicrobiology: revealing fecal microbiomes of ancient indigenous cultures. PLoS One. 2014;9(9):e106833. doi: 10.1371/journal.pone.0106833 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Fuller K. Hookworm: not a pre-Columbian pathogen. Med Anthropol. 1997;17(4):297–308. doi: 10.1080/01459740.1997.9966143 [DOI] [PubMed] [Google Scholar]
  • 12.Ferreira LF, de Araújo AJ, Confalonieri UE. The finding of eggs and larvae of parasitic helminths in archaeological material from Unai, Minas Gerais, Brazil. Trans R Soc Trop Med Hyg. 1980;74(6):798–800. doi: 10.1016/0035-9203(80)90205-9 [DOI] [PubMed] [Google Scholar]
  • 13.Kliks MM. Parasites in archaeological material from Brazil. Trans R Soc Trop Med Hyg. 1982;76(5):701. doi: 10.1016/0035-9203(82)90244-9 [DOI] [PubMed] [Google Scholar]
  • 14.Ferreira LF, de Araújo AJ, Confalonieri UE. The finding of helminth eggs in a Brazilian mummy. Trans R Soc Trop Med Hyg. 1983;77(1):65–7. doi: 10.1016/0035-9203(83)90017-2 [DOI] [PubMed] [Google Scholar]
  • 15.Ferreira LF, de Araújo AJG, Confalonieri UE. Parasites in archaeological material from Brazil: a reply to M. M. Kliks. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1983;77(4):565–6. doi: 10.1016/0035-9203(83)90142-6 [DOI] [PubMed] [Google Scholar]
  • 16.Reinhard K, Araújo A, Ferreira LF, Coimbra CE. American hookworm antiquity. Med Anthropol. 2001;20(1):96–101; discussion 101-4. doi: 10.1080/01459740.2001.9966190 [DOI] [PubMed] [Google Scholar]
  • 17.Faulkner CT, Patton S. Pre-Columbian hookworm evidence from Tennessee: a response to Fuller (1997). Med Anthropol. 2001;20(1):92–6; discussion 101-4. doi: 10.1080/01459740.2001.9966189 [DOI] [PubMed] [Google Scholar]
  • 18.Handelsman J, Rondon MR, Brady SF, Clardy J, Goodman RM. Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products. Chem Biol. 1998;5(10):R245-9. doi: 10.1016/s1074-5521(98)90108-9 [DOI] [PubMed] [Google Scholar]
  • 19.Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harbor symposia on quantitative biology. Cold Spring Harbor Laboratory Press. 1986. p. 263–73. [DOI] [PubMed] [Google Scholar]
  • 20.Hagan RW, Hofman CA, Hübner A, Reinhard K, Schnorr S, Lewis CM Jr, et al. Comparison of extraction methods for recovering ancient microbial DNA from paleofeces. Am J Phys Anthropol. 2020;171(2):275–84. doi: 10.1002/ajpa.23978 [DOI] [PubMed] [Google Scholar]
  • 21.Crossette E, Gumm J, Langenfeld K, Raskin L, Duhaime M, Wigginton K. Metagenomic Quantification of Genes with Internal Standards. mBio. 2021;12(1):e03173-20. doi: 10.1128/mBio.03173-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Taylor W, Bohm K, Dyet K, Weaver L, Pattis I. Comparative analysis of qPCR and metagenomics for detecting antimicrobial resistance in wastewater: a case study. BMC Res Notes. 2025;18(1):5. doi: 10.1186/s13104-024-07027-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Tito RY, Macmil S, Wiley G, Najar F, Cleeland L, Qu C, et al. Phylotyping and functional analysis of two ancient human microbiomes. PLoS One. 2008;3(11):e3703. doi: 10.1371/journal.pone.0003703 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Appelt S, Armougom F, Le Bailly M, Robert C, Drancourt M. Polyphasic analysis of a middle ages coprolite microbiota, Belgium. PLoS One. 2014;9(2):e88376. doi: 10.1371/journal.pone.0088376 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Brooks RH, Kaplan L, Cutler HC, Whitaker TW. Plant Material from a Cave on the Rio Zape, Durango, Mexico. Am antiq. 1962;27(3):356–69. doi: 10.2307/277801 [DOI] [Google Scholar]
  • 26.Meade T i m o t h y. A dietary analysis of coprolites from a prehistoric Mexican cave site. University of Nebraska—Lincoln. 1994. [Google Scholar]
  • 27.Reinhard K. Reestablishing rigor in archaeological parasitology. Int J Paleopathol. 2017;19:124–34. doi: 10.1016/j.ijpp.2017.06.002 [DOI] [PubMed] [Google Scholar]
  • 28.Borry M, Cordova B, Perri A, Wibowo M, Prasad Honap T, Ko J, et al. CoproID predicts the source of coprolites and paleofeces using microbiome composition and host DNA content. PeerJ. 2020;8:e9001. doi: 10.7717/peerj.9001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Hammerl EE, Baier MA, Reinhard KJ. Agave Chewing and Dental Wear: Evidence from Quids. PLoS One. 2015;10(7):e0133710. doi: 10.1371/journal.pone.0133710 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Wibowo MC, Yang Z, Borry M, Hübner A, Huang KD, Tierney BT, et al. Reconstruction of ancient microbial genomes from the human gut. Nature. 2021;594(7862):234–9. doi: 10.1038/s41586-021-03532-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Liu J, Gratz J, Amour C, Kibiki G, Becker S, Janaki L, et al. A laboratory-developed TaqMan Array Card for simultaneous detection of 19 enteropathogens. J Clin Microbiol. 2013;51(2):472–80. doi: 10.1128/JCM.02658-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Liu J, Gratz J, Amour C, Nshama R, Walongo T, Maro A, et al. Optimization of Quantitative PCR Methods for Enteropathogen Detection. PLoS One. 2016;11(6):e0158199. doi: 10.1371/journal.pone.0158199 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Rousselon N, Delgenès J-P, Godon J-J. A new real time PCR (TaqMan PCR) system for detection of the16S rDNA gene associated with fecal bacteria. J Microbiol Methods. 2004;59(1):15–22. doi: 10.1016/j.mimet.2004.05.007 [DOI] [PubMed] [Google Scholar]
  • 34.Ishii S, Kitamura G, Segawa T, Kobayashi A, Miura T, Sano D, et al. Microfluidic quantitative PCR for simultaneous quantification of multiple viruses in environmental water samples. Appl Environ Microbiol. 2014;80(24):7505–11. doi: 10.1128/AEM.02578-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kodani M, Winchell JM. Engineered combined-positive-control template for real-time reverse transcription-PCR in multiple-pathogen-detection assays. J Clin Microbiol. 2012;50(3):1057–60. doi: 10.1128/JCM.05987-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Zhu K, Suttner B, Pickering A, Konstantinidis KT, Brown J. A novel droplet digital PCR human mtDNA assay for fecal source tracking. Water Res. 2020;183:116085. doi: 10.1016/j.watres.2020.116085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Glassing A, Dowd SE, Galandiuk S, Davis B, Chiodini RJ. Inherent bacterial DNA contamination of extraction and sequencing reagents may affect interpretation of microbiota in low bacterial biomass samples. Gut Pathog. 2016;8:24. doi: 10.1186/s13099-016-0103-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Stinson LF, Keelan JA, Payne MS. Identification and removal of contaminating microbial DNA from PCR reagents: impact on low-biomass microbiome analyses. Lett Appl Microbiol. 2019;68(1):2–8. doi: 10.1111/lam.13091 [DOI] [PubMed] [Google Scholar]
  • 39.Corless CE, Guiver M, Borrow R, Edwards-Jones V, Kaczmarski EB, Fox AJ. Contamination and sensitivity issues with a real-time universal 16S rRNA PCR. J Clin Microbiol. 2000;38(5):1747–52. doi: 10.1128/JCM.38.5.1747-1752.2000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Philipp S, Huemer HP, Irschick EU, Gassner C. Obstacles of Multiplex Real-Time PCR for Bacterial 16S rDNA: Primer Specifity and DNA Decontamination of Taq Polymerase. Transfus Med Hemother. 2010;37(1):21–8. doi: 10.1159/000265571 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Goncalves MLC, da Silva VL, de Andrade CM, Reinhard K, da Rocha GC, Le Bailly M, et al. Amoebiasis distribution in the past: first steps using an immunoassay technique. Trans R Soc Trop Med Hyg. 2004;98(2):88–91. doi: 10.1016/s0035-9203(03)00011-7 [DOI] [PubMed] [Google Scholar]
  • 42.Morrow JJ, Reinhard KJ. Cryptosporidium parvum among coprolites from la Cueva de los Muertos Chiquitos (600–800 CE), Rio Zape Valley, Durango, Mexico. J Parasitol. 2016;102:429–35. [DOI] [PubMed] [Google Scholar]
  • 43.Cook GC. Enterobius vermicularis infection. Gut. 1994;35(9):1159–62. doi: 10.1136/gut.35.9.1159 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Wilke PJ, Hall HJ. Analysis of ancient feces: a discussion and annotated bibliography. Archaeological Research Facility, Dept. of Anthropology, University of California. 1975. [Google Scholar]
  • 45.Reinhard KJ, Bryant VM. Coprolite analysis: a biological perspective on archaeology. Archaeological method and theory. 1992;4:245–88. [Google Scholar]
  • 46.Zhu KJ, Suttner B, Knee J, Capone D, Moe CL, Stauber CE, et al. Elevated fecal mitochondrial dna from symptomatic norovirus infections suggests potential health relevance of human mitochondrial dna in fecal source tracking. Environ Sci Technol Lett. 2022;9(6):543–50. doi: 10.1021/acs.estlett.2c00140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Capone D, Bakare T, Barker T, Chatham AH, Clark R, Copperthwaite L, et al. Risk Factors for Enteric Pathogen Exposure among Children in Black Belt Region of Alabama, USA. Emerg Infect Dis. 2023;29. doi: 10.3201/eid2912.230780 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.WAGNER EG, LANOIX JN. Excreta disposal for rural areas and small communities. Monogr Ser World Health Organ. 1958;39:1–182. [PubMed] [Google Scholar]
  • 49.Penakalapati G, Swarthout J, Delahoy MJ, McAliley L, Wodnik B, Levy K, et al. Exposure to Animal Feces and Human Health: A Systematic Review and Proposed Research Priorities. Environ Sci Technol. 2017;51(20):11537–52. doi: 10.1021/acs.est.7b02811 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Delahoy MJ, Wodnik B, McAliley L, Penakalapati G, Swarthout J, Freeman MC, et al. Pathogens transmitted in animal feces in low- and middle-income countries. Int J Hyg Environ Health. 2018;221(4):661–76. doi: 10.1016/j.ijheh.2018.03.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Santiago-Rodriguez TM, Narganes-Storde YM, Chanlatte L, Crespo-Torres E, Toranzos GA, Jimenez-Flores R, et al. Microbial communities in pre-columbian coprolites. PLoS One. 2013;8(6):e65191. doi: 10.1371/journal.pone.0065191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Tito RY, Knights D, Metcalf J, Obregon-Tito AJ, Cleeland L, Najar F, et al. Insights from characterizing extinct human gut microbiomes. PLoS One. 2012;7(12):e51146. doi: 10.1371/journal.pone.0051146 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Krauth SJ, Coulibaly JT, Knopp S, Traoré M, N’Goran EK, Utzinger J. An in-depth analysis of a piece of shit: distribution of Schistosoma mansoni and hookworm eggs in human stool. PLoS Negl Trop Dis. 2012;6(12):e1969. doi: 10.1371/journal.pntd.0001969 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Sawyer S, Krause J, Guschanski K, Savolainen V, Pääbo S. Temporal patterns of nucleotide misincorporations and DNA fragmentation in ancient DNA. PLoS One. 2012;7(3):e34131. doi: 10.1371/journal.pone.0034131 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Briggs AW, Stenzel U, Meyer M, Krause J, Kircher M, Pääbo S. Removal of deaminated cytosines and detection of in vivo methylation in ancient DNA. Nucleic Acids Res. 2010;38(6):e87. doi: 10.1093/nar/gkp1163 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Huggett JF, Novak T, Garson JA, Green C, Morris-Jones SD, Miller RF, et al. Differential susceptibility of PCR reactions to inhibitors: an important and unrecognised phenomenon. BMC Res Notes. 2008;1:70. doi: 10.1186/1756-0500-1-70 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Knapp M, Clarke AC, Horsburgh KA, Matisoo-Smith EA. Setting the stage - building and working in an ancient DNA laboratory. Ann Anat. 2012;194(1):3–6. doi: 10.1016/j.aanat.2011.03.008 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Elham Kazemirad

10 Mar 2025

Dear Dr. Capone,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 24 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Elham Kazemirad, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your manuscript, please provide additional information regarding the specimens used in your study. Ensure that you have reported human remain specimen numbers and complete repository information, including museum name and geographic location.

If permits were required, please ensure that you have provided details for all permits that were obtained, including the full name of the issuing authority, and add the following statement:

'All necessary permits were obtained for the described study, which complied with all relevant regulations.'

If no permits were required, please include the following statement:

'No permits were required for the described study, which complied with all relevant regulations.'

For more information on PLOS ONE's requirements for paleontology and archeology research, see https://journals.plos.org/plosone/s/submission-guidelines#loc-paleontology-and-archaeology-research .

3.  We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

4. Thank you for stating the following financial disclosure: [D.C. was supported in part by an NIH T32 Fellowship (5T32ES007018-44). The authors declare no competing financial interest.]. 

Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.""

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

5. Thank you for stating in your Funding Statement: [D.C. was supported in part by an NIH T32 Fellowship (5T32ES007018-44). The authors declare no competing financial interest.].

Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now.  Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement.

Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf.

6. We note that there is identifying data in the Supporting Information file < Supplemental_v2b.docx>. Due to the inclusion of these potentially identifying data, we have removed this file from your file inventory. Prior to sharing human research participant data, authors should consult with an ethics committee to ensure data are shared in accordance with participant consent and all applicable local laws.

Data sharing should never compromise participant privacy. It is therefore not appropriate to publicly share personally identifiable data on human research participants. The following are examples of data that should not be shared:

-Name, initials, physical address

-Ages more specific than whole numbers

-Internet protocol (IP) address

-Specific dates (birth dates, death dates, examination dates, etc.)

-Contact information such as phone number or email address

-Location data

-ID numbers that seem specific (long numbers, include initials, titled “Hospital ID”) rather than random (small numbers in numerical order)

Data that are not directly identifying may also be inappropriate to share, as in combination they can become identifying. For example, data collected from a small group of participants, vulnerable populations, or private groups should not be shared if they involve indirect identifiers (such as sex, ethnicity, location, etc.) that may risk the identification of study participants.

Additional guidance on preparing raw data for publication can be found in our Data Policy (https://journals.plos.org/plosone/s/data-availability#loc-human-research-participant-data-and-other-sensitive-data) and in the following article: http://www.bmj.com/content/340/bmj.c181.long.

Please remove or anonymize all personal information (Name) ensure that the data shared are in accordance with participant consent, and re-upload a fully anonymized data set. Please note that spreadsheet columns with personal information must be removed and not hidden as all hidden columns will appear in the published file.

7.  Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information .

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Partly

Reviewer #4: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: N/A

Reviewer #2: N/A

Reviewer #3: No

Reviewer #4: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

Reviewer #4: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

Reviewer #4: Yes

**********

Reviewer #1: Many thanks to the editor for asking me to review this paper, and many thanks to the authors for their contribution to the field.

Here are my comments. Obviously I may have unwillingly distorted the points made by the authors and I’m fully open to be contradicted and shown to be wrong.

L 27-28 : it is true that modern molecular tools such as PCR can be used in this kind of studies, but this is known since several decades now. So I’d tend to put the final emphasis of your abstract on something else you effectively demonstrated in your paper rather than this.

L. 42 : Note that molecular identification of ancient pathogens or other past organisms has also, and still does, generated much debate. I’d suggest diminishing the idea of opposed methods and preferring the idea of proxy complementarity. Many studies showed how looking in parallel for molecular signatures, micro and macro remains, where actually much more informative rather than only aDNA or microscopy for instance.

L. 49-51 : once again, studying ancient pathogens from coprolites through their molecular signature is not something new in 2025 but your wording may suggest the contrary. See for example : Appelt S, Armougom F, Le Bailly M, Robert C, Drancourt M. Polyphasic analysis of a middle ages coprolite microbiota, Belgium. PLoS One. 2014 Feb 28;9(2):e88376. doi: 10.1371/journal.pone.0088376. PMID: 24586319; PMCID: PMC3938422. And it included microscopy-based diagnosis.

L. 51 : could you be more specific on how such knowledge could expand our understanding of how peoples lived ?

L. 61 : as you are not solely speaking to molecular biologists and microbiologists I think you should be more accurate on site description and chronological methods, even if it was previously published. You are also speaking to paleo/archaeo scientists in this paper. Note that you mentioned “previously collected […] material” (l. 57), a naive reader would then certainly understand that there is previous studies of these materials. You certainly should cite them here too.

L.66-71 Could you please specify if this MSC is located in a clean room dedicated to aDNA analysis, or if it is at least dedicated to aDNA samples (meaning, it never saw any modern feces sample)?

L.118-130 : Could you tell more in the core paper about these targets? How long are their amplicons, were they previously tested on modern samples? I think these informations should be made clear in the core text without having to dive in the supplementary files.

L. 148-159: Wouldn’t it be appropriate to also test non-human targets?

Is there any control performed with the surrounding sediment to distinguish the true feces’ content from surrounding leaching and environmental agents?

L. 201-203 : Did you have the opportunity to test the exact same coprolites (in order to know if some of them were positive under the microscope but not after PCR).

L. 213-216 : this also pleads for mentioning multi-proxy approaches I mentioned before. Far from diminishing your own approach, as you are potentially able to highlight it.

L. 218-212 : Aside from the debate in itself, I would highly recommend to chose another wording for this sentence, as the detection of E. vermicularis per se does not support at all the absence of other helminths in pre-contact America. You are here substantially saying that most, if not all, published detections of Ascaris and hookworms from pre-contact America are misidentification. It’s a strong statement that should be based on case by case counter-identification based on published pictures, and not derived from the molecular detection of E. vermicularis within these 10 samples (I’m not working on this region/period, so don’t worry about me being triggered here).

L. 227 : no other animals were tested if I’m correct (like, most commonly encountered cave dwelling mammals then and now).

L. 229 : but you did not mention any test performed with sediment samples from the sedimentary layers surrounding these coprolites.

L. 233 : if most of these pathogens are shared between human and non-human hosts, then how could you conclude mostly about human behavior and waste management? I know there is a whole published archaeological background that could be used here to support your point, but you are not using it. So a naive reader can only think you decided a little bit arbitrarily it was human rather than non-human coprolites and pathogens, to document human waste management.

L. 235: Did Shigella and human mtDNA detection match the same coprolite?

L. 252-261 : You did not provide any sequencing set that could be compared with environmental samples and assessed for aDNA damage patterns. Wouldn’t be considered as limitations?

As a whole I think this paper is interesting when suggesting that a well documented qPCR assay for modern samples and targeting a large variety of enteric pathogens could be used in paleodiagnosis. But as it is written at least, it is not at all integrated in archaeo/paleosciences. While it seems to highlight molecular and PCR based approaches as something new, it does not follow usual standards of authenticity in paleomicrobiology (typically providing sequence data showing damage patterns and control samples from the surrounding sedimentary layers, or at least discussions about depositional and post depositional process). It does not introduce at all the archaeological and sampling context, conditions and methods, and barely mentions previous studies from the same site. Finally, it tries to address the biological origin of the samples, but did not mention any real attempt to falsify the human origin hypothesis. It leaves me with the feeling that the paper, though technically interesting, did not, even remotely, attempt to address the archaeo/paleoscientific questions it was supposed to.

Reviewer #2: The authors present a study of 10 paleofeces from Mexico. They used a pre-amplification method followed by a qPCR analysis and a dPCR analysis to examine enteric pathogens and human mtDNA respectively. The manuscript was easy to read and follow. I am conviced that the authors have detected ancient enteric pathogens, which is of scientific interest. However, I have a few concerns I would like to see addressed:

1. The authors address that they do not use metagenomic analysis, even though that is the norm in the ancient DNA field. Their arguments against it should be backed up by more data. For example in lines 246 and 247, the authors claim "Metagenomics

has a higher limit of detection than PCR, and sequencing may miss low abundance genomes" but do not provide a citation for this statement. I would be surprised if this were true. Especially as the authors do not discuss a large bais they will have when using PCR primers: ancient DNA is very short and most fragments will not be amplified using primers so they are able to see only the very well preserved, long DNA fragments using this method. I would rather say the strength of this method could be cost, which is important. NGS library preperation and sequencing to levels deep enough to detect these microbes would be far more expensive than this method.

2. I would like a discussion of how the TaqMan kit they use could cause biases. This kit is designed to be used for cDNA and not genomic DNA and could thus cause biases due to non-specific amplification.

3. My biggest concern is the human mtDNA. Without sequencing it is impossible to claim that the human mtDNA comes from a true ancient source. In my experience with ancient DNA, samples themselves are often contaminated with modern human DNA. Thus a negative extraction control does not indicate that there is no potential modern human contamination. One would need to sequence this DNA and show patterns of ancient damage to be convincing that this comes from a human source. I think that making NGS libraries and sequencing are outside the scope of this study, however I would like this potential modern contamination discussed.

4. My last comment is minor: There is a typo in line 74 "The samples from were high in fiber [22]". I assume a word is missing?

Reviewer #3: Sequencing of Samples: The manuscript presents interesting findings, but an essential issue is the lack of sequencing for all amplified products. It is necessary to sequence all samples to confirm that the amplification is specific and accurately represents the target organisms. Without sequencing, there is a significant risk of false positives, particularly when working with microbial eukaryotes.

Monitoring Evolution Over Time: The study could be greatly strengthened by incorporating a temporal analysis of the evolution of these organisms. This would add a valuable dimension to the research, providing insights into changes in pathogen profiles over time and improving the impact of the study.

Language and Terminology: The manuscript would benefit from a thorough review of the language for clarity and readability. There are typographical errors that should be corrected. Additionally, statements such as "Blastocystis is a pathogen" should be carefully reconsidered. The pathogenicity of Blastocystis remains debated, and it would be more appropriate to refer to it as an organism commonly found in the gut rather than labeling it as a definitive pathogen.

Minor suggestions:

Clarification of Pathogenicity Terminology: The manuscript states that Blastocystis is a pathogen. Given the ongoing debate regarding its pathogenicity, the authors should revise this statement to reflect current scientific consensus, such as referring to it as a "commonly detected gut microbe" rather than a definitive pathogen.

Grammar, Spelling, and Typographical Errors: The manuscript contains typographical and grammatical issues that should be corrected. A careful proofreading is necessary to improve readability and clarity.

Consistency in Terminology: Ensure that terminology such as paleofeces vs. coprolites is used consistently throughout the manuscript to avoid confusion.

PCR and qPCR Methodological Justification: The authors should provide a stronger justification for their choice of PCR/qPCR as the primary detection method without sequencing. If sequencing is not included, they should explicitly discuss the limitations and potential risks of false positives.

Table Formatting and Data Presentation:

Table 1: Ensure uniform formatting of columns and clearly indicate sample sizes for each prevalence calculation.

Consider adding confidence intervals where applicable for prevalence values.

Figures and Legends:

Figures should have more descriptive legends to ensure they are self-explanatory.

If possible, improve resolution and clarity of any images, particularly those displaying results.

Reference Updates: Ensure all references are up-to-date and correctly formatted according to PLOS ONE guidelines.

Statistical Interpretation:

Where applicable, clarify the statistical significance of the findings.

If sample sizes are small, acknowledge this limitation explicitly.

Reviewer #4: This study applies modern molecular techniques to analyze ancient desiccated feces (paleofeces) collected from caves in the Rio Zape Valley, Mexico (725–920 CE). Paleofeces can offer invaluable insights into ancient dietary practices, human migration, and pathogen exposure. The authors leverage PCR pre-amplification followed by multi-parallel qPCR to detect the presence of 30 enteric pathogens, a substantial advancement over traditional methods like microscopy, which has been used for identifying soil-transmitted helminths but carries a risk of misclassification due to observer bias. The study provides important insights, as it represents the first molecular detection of several pathogens in paleofeces, including Blastocystis spp., atypical enteropathogenic E. coli, enterotoxigenic E. coli, Shigella spp., and E. coli O157:H7. These findings demonstrate the power of modern molecular tools like PCR to detect degraded ancient DNA and highlight how PCR can be applied to study pathogens in ancient biological materials.

However, there are several critical technical aspects that need more clarification to ensure reproducibility and robustness in the methodology:

1. Origin and Dating of Samples:

o The authors do not specify how the dating of the samples was performed. Detailing this information would strengthen the study's credibility and accuracy in placing these samples in their correct historical context.

2. DNA Extraction:

o The study does not mention the use of a dedicated clean room for ancient DNA (aDNA) extraction. Ancient DNA is highly degraded and prone to contamination from modern DNA. Best practices for aDNA extraction require a physically separated clean lab with HEPA-filtered positive-pressure air and full-body PPE (including face shields, lab coats, and gloves). The study should clarify whether these practices were implemented.

o Additionally, Uracil-DNA Glycosylase (UDG) treatment, which helps correct DNA damage from deamination, is not mentioned. If UDG was not used, the authors should acknowledge this limitation in their study. If it was used, the specific procedure should be described.

o The authors should also provide more information about DNA purity (e.g., A260/A280 and A260/A230 ratios) and whether they assessed the quality and fragmentation of the DNA (e.g., using a Bioanalyzer or TapeStation). Without assessing DNA integrity, there is a risk that the DNA may be too degraded to amplify efficiently, potentially affecting the results.

3. qPCR Methodology:

o The study mentions using 38 forward and 38 reverse primers from IDT (Coralville, Iowa), but the selection and validation of these primers for use with degraded or ancient DNA are not described. The authors should explain if these primers were specifically tested for their ability to work with low-abundance or fragmented DNA. It would be helpful to include a discussion of how they ensured the primers' efficacy in amplifying ancient DNA sequences.

4. Digital PCR:

o The use of digital PCR (dPCR) to detect human mitochondrial DNA (mtDNA) in paleofeces is a sound approach to confirm the human origin of the samples. However, modern human mtDNA contamination is a common issue in laboratories, as it is highly abundant. The authors should address the potential for contamination and explain how they mitigated the risk of false positives for human fecal origin. This could be crucial in ensuring the accuracy of their findings regarding the genuine ancient DNA sequences.

Results:

Did the data retrieved from this study deposited in online repositories?

________________________________________

The study presents a methodologically strong approach, combining modern molecular tools like PCR and dPCR with innovative techniques for detecting pathogens in ancient feces. However, there are critical technical gaps, particularly regarding cleanroom practices, DNA extraction protocols, and primer validation for ancient DNA. If these precautions were not followed, the results might be subject to contamination or bias. I recommend major revisions to address these concerns and strengthen the overall reliability and reproducibility of the methodology.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 Oct 22;20(10):e0318140. doi: 10.1371/journal.pone.0318140.r002

Author response to Decision Letter 1


6 Jun 2025

We appreicate the author's time and thoughtfulness. We feel the feedback has greatly strengthened the manuscript. Please see the attached document for our point by point response to comments.

Attachment

Submitted filename: Response to Reviewers.docx

pone.0318140.s008.docx (54.5KB, docx)

Decision Letter 1

Elham Kazemirad

9 Jul 2025

Dear Dr. Capone,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 23 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Elham Kazemirad, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #3: (No Response)

Reviewer #4: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

Reviewer #4: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: N/A

Reviewer #2: N/A

Reviewer #3: No

Reviewer #4: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: (No Response)

**********

Reviewer #1:  I have read the authors' responses to my comments. While the article still presents some of the weaknesses previously identified by myself and the other reviewers, I acknowledge that the authors have addressed these points honestly and have clearly acknowledged and discussed the limitations. In light of this transparent and constructive approach, I believe the article is suitable for publication.

Reviewer #2:  The authors have adequatly addressed my concerns and I believe the manuscript is now ready for publication.

Reviewer #3:  Thank you for your revision and responses. I appreciate the efforts made to improve the manuscript. However, after reviewing the revised version and the point-by-point response, I remain unconvinced that my concerns have been adequately addressed. Below, I outline the key issues that persist:

1. Sample Size and Statistical Justification

While I understand the constraints of working with ancient material, the manuscript still lacks any form of quantitative justification for the sample size (n = 10), nor does it provide a clear explanation of the implications of such a limited dataset. There is no power analysis or alternative rationale. This omission weakens the strength of the claims, especially those that discuss prevalence or make broader epidemiological inferences. I strongly recommend softening these conclusions and clearly communicating the exploratory nature of the work.

2. Overinterpretation of Results

Several conclusions—such as the suggestion that "enteric infections were common" among the Loma San Gabriel people—are not sufficiently supported given the data. This interpretation does not take into account:

the potential for false positives, especially with low-level amplification,

lack of authentication for ancient DNA (e.g., no sequencing or damage pattern analysis),

limited replication and variability in concordance between replicates,

and absence of confirmatory tests (e.g., amplicon sequencing or histological correlation).

These concerns are not fully addressed in the revised manuscript.

3. Limited Replication and Concordance

The replication data show that 35% of targets were detected in only one of two or three replicates. This level of variability raises questions about reproducibility and the robustness of detections. While some variability can be expected in low-biomass, degraded samples, the extent observed here undermines confidence in the findings. This needs to be more transparently acknowledged in the main text and considered in the interpretation of prevalence data.

4. Molecular Authentication of Ancient DNA

The authors did not incorporate any ancient DNA authentication strategies—such as damage pattern analysis, uracil-DNA glycosylase treatment, or independent validation through sequencing—to demonstrate that the detected targets represent ancient rather than modern or environmental contamination. Given that the study’s novelty hinges on being the “first” to report certain pathogens in paleofeces, this omission is significant and weakens confidence in the findings.

5. Insufficient Biological Context for Detected Taxa

The manuscript continues to list pathogen-associated genes without offering substantive biological interpretation. While additional references were added, the discussion remains superficial. For example, the ecological relevance, potential zoonotic transmission, or expected prevalence in ancient vs. modern contexts are not explored for many of the bacteria or protozoa. Without such context, the findings are descriptive rather than explanatory.

6. Wording and Clarity

Despite some edits, the manuscript continues to rely on vague or subjective language (e.g., “diverse,” “common,” “novel”). I recommend further revision to use precise, evidence-based language. The interpretation of results should be framed with appropriate caution given the study’s limitations.

7. Controls and Contamination

The authors note that 16S rRNA genes were detected in negative controls and attribute this to contamination of commercial reagents. While this is plausible and a known issue, it underscores the need for independent validation (e.g., sequencing amplicons or removing affected targets from interpretation). This issue is not sufficiently addressed in the discussion.

8. Conclusions

The authors conclude that modern molecular techniques are effective for detecting pathogens in paleofeces. While this may be true in principle, the methods applied here lack several key elements (e.g., authentication, replication consistency, host confirmation in most samples) that are critical in ancient DNA studies. The paper would benefit from reframing this conclusion as a proof-of-concept rather than an authoritative epidemiological report.

Summary

In its current form, this manuscript presents technically interesting data but overstates its conclusions. Additional caution in interpretation, further discussion of limitations, and ideally, more robust molecular validation or justification would be needed for the study to meet publication standards. I recommend major revision before further consideration.

Reviewer #4:  - Use of Class IIA Biological Safety Cabinet Instead of a Clean Room

DNA extractions were performed in a Class IIA BSC, disinfected with 10% bleach, 70% ethanol, and UV light, rather than a dedicated aDNA clean room. Class IIA BSC Provides a sterile workspace with laminar airflow and UV sterilization but lacks positive pressure, HEPA filtration to remove airborne DNA, and physical separation of pre- and post-PCR areas. BSCs are designed for biosafety, not aDNA-specific contamination control. aDNA Clean Room Features positive pressure to prevent external DNA entry, HEPA-filtered air, UV-irradiated surfaces, and segregated pre- and post-PCR facilities to prevent amplicon carryover. These are essential for aDNA to avoid modern DNA contamination, which is abundant in microbial-rich environments like paleofeces. The BSC’s limitations likely contributed to the 16S rRNA contamination, as environmental DNA (e.g., from lab air, surfaces) could have entered during grinding or transfer. This is critical for aDNA, where low-yield, degraded samples are easily overwhelmed by modern DNA.

- The study does not report removing the outer layer of paleofeces samples before extraction, a standard practice in aDNA studies to eliminate surface contaminants. Paleofeces from archaeological contexts are exposed to environmental DNA (e.g., soil microbes, animal feces) during burial and excavation. The outer layer, especially in a mixed midden (Ref 28), is likely contaminated with modern or non-target DNA. This could lead to false positives or misattribution of microbial signals.

- The study does not mention applying UV irradiation to paleofeces samples prior to DNA extraction, a critical step in aDNA protocols to degrade modern surface DNA contamination. UV irradiation (e.g., 254 nm, 30–60 minutes) is commonly used in aDNA studies to cross-link and degrade modern DNA on sample surfaces, reducing contamination risks from handling, excavation, or environmental exposure. Paleofeces, being organic and porous, are particularly prone to modern microbial DNA adhesion.

- The study relies on real-time PCR (TAC) and digital PCR fluorescence signals (Cq values, manual thresholding) without sequencing amplicons to confirm their identity. Sequencing (e.g., Sanger or next-generation sequencing) is essential in aDNA studies to verify that amplified products are ancient, not modern contaminants or non-specific amplifications.

- The primers and extraction method were validated on modern feces (Ref 34), not aDNA, which is fragmented and chemically modified (e.g., deamination). This risks false negatives or reduced sensitivity.

- The absence of photographic documentation of the paleofeces (coprolites) in the study is a significant oversight, as visual evidence of their appearance could have provided critical clues about their probable origin (human vs. canine) based on shape, size, texture, or dietary inclusions, especially in the mixed human-canine Rio Zape midden (Ref 28)

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org

Decision Letter 2

Elham Kazemirad

28 Aug 2025

Dear Dr. Capone,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 12 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Elham Kazemirad, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #3: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #3: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #3: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #3: No

**********

Reviewer #3: Here’s the thing: the study is interesting and shows proof-of-concept that targeted qPCR can recover enteric pathogen–associated gene signals from paleofeces. However, as currently written the manuscript over-claims (prevalence, “first detections”) and lacks the experimental and data transparency required to support those organismal and epidemiological conclusions. Major revision is required. Below I list the problems that must be fixed and the concrete actions I would insist on before recommending acceptance.

Major issues (must be addressed)

Sequence confirmation of positives

qPCR signal alone is insufficient to claim organismal detection or novelty. For all key positive assays (those used to claim “first detection” or prevalence), the authors must provide sequence confirmation (Sanger or amplicon sequencing) of the amplified products and deposit sequences (GenBank accessions). If sequencing is not possible, all organismal/novelty claims must be downgraded to “qPCR signal consistent with X — sequence confirmation not obtained.”

Transparent replicate-calling policy and raw data

Provide a clear “Calling policy and concordance” subsection in Methods that states how positives were called (e.g., Cq threshold, replicate rule).

Supply a supplementary table with per-replicate raw Cq/Ct values for every assay, sample, extraction blank, and no-template control.

In the main results (or Table 1) show prevalence under both a conservative rule (e.g., ≥2/3 replicates positive) and a liberal rule (any replicate positive). This lets readers judge robustness.

Negative controls and contamination handling

Present extraction/reagent blank Cq values in full.

Any target detected in negative controls should be excluded from prevalence claims unless sequence-confirmed and shown to differ from reagent contaminants. Describe how control results modified calling.

Host identification

Human mtDNA was detected in only 1/10 samples. Either test for common alternative vertebrate mtDNA markers to exclude nonhuman origin for mtDNA-negative samples or explicitly flag those samples as host-uncertain and remove species-specific interpretation from them.

Overstated interpretation and “first detection” claims

Reword statements that imply population-level prevalence or definitive ancient infection. Replace “first detection” with provisional language unless sequence-confirmed. Example for Abstract: “These results provide proof-of-concept that targeted qPCR can recover enteric pathogen-associated gene signals from paleofeces; prevalence estimates are exploratory and constrained by sample size and taphonomic uncertainty.”

Reproducibility / independent validation (preferred)

For the most novel/important detections, independent replication in a second laboratory or with a second method (amplicon sequencing, different primer set) is strongly recommended.

Minor / editorial issues (to be fixed)

Correct spelling errors and formatting artifacts (e.g., “dessicated” → desiccated; remove Word track-change remnants and “Formatted:” markers).

Standardize and italicize Latin names (Blastocystis spp., Entamoeba histolytica, etc.) and acronyms (define qPCR, Cq on first use).

De-duplicate and correct references (several duplicated entries noted).

Ensure figure and table legends are self-contained and that all acronyms used in tables are defined.

Provide per-table legends for all supplementary data files.

Data availability (required for PLOS policy)

Deposit sequence data (Sanger/amplicon reads) to GenBank (provide accession numbers) and any raw sequencing reads to SRA if applicable.

Provide downloadable CSV/TSV files with all per-replicate qPCR raw Cq/Ct values, negative-control Cq values, sample metadata (sample ID, context/depth/dating, extraction batch, lot numbers where relevant), and the exact calling-policy script or spreadsheet. Upload these to a public repository (Dryad, Zenodo, figshare) and link them in the Data Availability Statement.

Suggested concrete edits you can paste

Abstract (replace opening): “These results provide proof-of-concept that targeted qPCR can recover enteric pathogen-associated gene signals from paleofeces; prevalence estimates are exploratory and constrained by sample size and taphonomic uncertainty.”

Methods: add subsection “Calling policy and concordance” detailing Cq thresholds and replicate rules.

Results/Table 1: add columns “Conservative (≥2/3 positives)” and “Liberal (any positive)”.

Ethical / publication concerns

I found no evidence of dual publication or ethical misconduct beyond the contamination/control concerns already raised. The main issue is analytic rigor and transparency; once the data and sequences are provided and controls addressed, ethical concerns will be resolved.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org

PLoS One. 2025 Oct 22;20(10):e0318140. doi: 10.1371/journal.pone.0318140.r006

Author response to Decision Letter 3


12 Sep 2025

Editor at PLOS ONE,

Please see our cover letter for our response to the request for revision.

Regards,

Drew Capone

Attachment

Submitted filename: Response_to_Reviewers_R2_auresp_3.docx

pone.0318140.s010.docx (36.4KB, docx)

Decision Letter 3

Elham Kazemirad

16 Sep 2025

Targeted pathogen profiling of ancient feces reveals common enteric infections in the Rio Zape Valley, 725-920 CE

PONE-D-25-01954R3

Dear Dr. Capone,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support .

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Elham Kazemirad, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Elham Kazemirad

PONE-D-25-01954R3

PLOS ONE

Dear Dr. Capone,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Elham Kazemirad

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. qPCR assays.

    (DOCX)

    pone.0318140.s001.docx (80.8KB, docx)
    S2 Table. qPCR QA/QC.

    (DOCX)

    pone.0318140.s002.docx (46.1KB, docx)
    S1 Fig. Amplification curves.

    (DOCX)

    pone.0318140.s003.docx (166.8KB, docx)
    S3 Table. MIQE Checklist.

    (DOCX)

    pone.0318140.s004.docx (50.4KB, docx)
    S4 Table. dPCR assay.

    (DOCX)

    pone.0318140.s005.docx (56.5KB, docx)
    S5 Table. Supplemental data file.

    (XLSX)

    pone.0318140.s006.xlsx (9.9KB, xlsx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0318140.s008.docx (54.5KB, docx)
    Attachment

    Submitted filename: Response to Reviewers_R2.docx

    pone.0318140.s009.docx (36.4KB, docx)
    Attachment

    Submitted filename: Response_to_Reviewers_R2_auresp_3.docx

    pone.0318140.s010.docx (36.4KB, docx)

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES